First Wave BioPharma CEO James Sapirstein to Participate in 2024 Longwood Healthcare Leaders Conference
April 15, 2024 07:00 ET
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
April 05, 2024 16:05 ET
|
23andMe, Inc.
23ME-01473, antibody targeting ULBP6: Data will be presented on the discovery and biology of ULBP6, and the potential to restore natural killer and T cell-mediated anti-tumor immunity by targeting...
Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 27, 2024 16:01 ET
|
Celcuity Inc.
Dosed the first patient in a Phase 1b/2 trial evaluating gedatolisib in combination with darolutamide for the treatment of metastatic castration resistant prostate cancer Presented nonclinical data...
CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB)
March 19, 2024 10:00 ET
|
Charm Therapeutics
PRESS RELEASE CHARM Therapeutics Announces Foundation of Scientific Advisory Board (SAB) LONDON – 19 March 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a 3D deep-learning research company...
Global Astaxanthin Market Size is projected to reach USD 7,536.19 million by 2031, growing at a CAGR of 16.78%: Straits Research
March 13, 2024 09:10 ET
|
Straits Research Private Limited
New York, United States, March 13, 2024 (GLOBE NEWSWIRE) -- Astaxanthin is produced by the yeast fungus Xanthophyllomyces dendrorhous and the freshwater microalgae Haematococcus Pluvialis....
How Do Companies Avert Further Frustration among Neurologists Due to Relyvrio’s (Amylyx) Phase 3 Failure and Donanemab’s (Lilly) FDA delay?
March 12, 2024 15:10 ET
|
Spherix Global Insights
EXTON, PA, March 12, 2024 (GLOBE NEWSWIRE) -- For neurologists tasked with delivering the distressing diagnosis of Amyotrophic Lateral Sclerosis (ALS) or Alzheimer’s Disease (AD), the upcoming...
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma
March 11, 2024 07:00 ET
|
Replay Bio
Replay’s cell therapy product company Syena announces first patient dosed in Phase 1/2 study of TCR-NK cell therapy for multiple myeloma Phase 1/2 clinical study of NY-ESO-1 TCR/IL-15 NK for relapsed...
NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial
March 07, 2024 07:00 ET
|
NodThera
NodThera Ltd (“NodThera” or the “Company”) NodThera’s NLRP3 Inhibitor NT-0796 Reverses Neuroinflammation in Parkinson’s Disease Phase Ib/IIa Trial Brain-penetrant NLRP3 inflammasome inhibitor...
Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024
March 07, 2024 04:00 ET
|
Oxford BioTherapeutics
OGAP®-Verify allows for significantly enhanced sensitivity and specificity for improved target selection, dramatically accelerating drug target discoveryOGAP-Verify is now more sensitive than...
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
March 07, 2024 03:00 ET
|
Persica Pharmaceuticals
Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held,...